OHA COVID-19 Webinar Series for Health Care Providers

January 14, 2021

Dawn Mautner, MD, MS
Ariel Smits, MD MPH
Tanya Kapka, MD, MPH
Dana Hargunani, MD, MPH
Agenda Items

• COVID-19 epi update
• COVID-19 vaccine update
• CDC and OHA guidance
• Literature review
• Closing
COVID-19 Update
As of January 13th:

- 129,109 total cases
- 7,123 hospitalized cases
- 1,708 deaths
COVID-19 Situation in Oregon

For the week of January 4-10:
• 8,150 new cases were recorded
  – Up 3% over prior week’s total
• 357 hospitalizations, largely unchanged from prior week
• 107 Oregonians died in association with COVID-19

From January 3-9:
• 8.2% of test results were positive
## COVID-19 Cases by Race

**Table 3. Severity and rates of COVID-19 by race**

<table>
<thead>
<tr>
<th>Race</th>
<th>Cases</th>
<th>% of total cases</th>
<th>Cases per 100,000</th>
<th>Hospitalized</th>
<th>% Hospitalized</th>
<th>Deaths</th>
<th>Case fatality</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 1 race</td>
<td>2,009</td>
<td>1.6</td>
<td>1,000</td>
<td>126</td>
<td>6.3</td>
<td>35</td>
<td>1.7</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>2,285</td>
<td>1.8</td>
<td>4,688</td>
<td>186</td>
<td>8.1</td>
<td>29</td>
<td>1.3</td>
</tr>
<tr>
<td>Asian</td>
<td>4,036</td>
<td>3.2</td>
<td>2,228</td>
<td>262</td>
<td>6.5</td>
<td>49</td>
<td>1.2</td>
</tr>
<tr>
<td>Black</td>
<td>3,073</td>
<td>2.4</td>
<td>3,806</td>
<td>226</td>
<td>7.4</td>
<td>39</td>
<td>1.3</td>
</tr>
<tr>
<td>Not Available</td>
<td>24,110</td>
<td>19.0</td>
<td></td>
<td>620</td>
<td>2.6</td>
<td>238</td>
<td>1.0</td>
</tr>
<tr>
<td>Other</td>
<td>30,490</td>
<td>24.1</td>
<td>23,117</td>
<td>1,289</td>
<td>4.2</td>
<td>135</td>
<td>0.4</td>
</tr>
<tr>
<td>Pacific Islander</td>
<td>1,150</td>
<td>0.9</td>
<td>6,923</td>
<td>119</td>
<td>10.3</td>
<td>14</td>
<td>1.2</td>
</tr>
<tr>
<td>White</td>
<td>59,455</td>
<td>47.0</td>
<td>1,662</td>
<td>4,164</td>
<td>7.0</td>
<td>1,074</td>
<td>1.8</td>
</tr>
<tr>
<td>Total</td>
<td>126,608</td>
<td>100.0</td>
<td>2,989</td>
<td>6,992</td>
<td>5.5</td>
<td>1,613</td>
<td>1.3</td>
</tr>
</tbody>
</table>
## COVID-19 Cases by Ethnicity

### Table 4. Severity and rates of COVID-19 by ethnicity

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Cases</th>
<th>% of total cases</th>
<th>Cases per 100,000</th>
<th>Hospitalized</th>
<th>% Hospitalized</th>
<th>Deaths</th>
<th>Case fatality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hispanic</td>
<td>34,679</td>
<td>27</td>
<td>6,377</td>
<td>1,476</td>
<td>4.3</td>
<td>159</td>
<td>0.5</td>
</tr>
<tr>
<td>Not Hispanic</td>
<td>60,781</td>
<td>48</td>
<td>1,646</td>
<td>4,286</td>
<td>7.1</td>
<td>1,033</td>
<td>1.7</td>
</tr>
<tr>
<td>Unknown</td>
<td>31,148</td>
<td>25</td>
<td>1,230</td>
<td>3.9</td>
<td></td>
<td>421</td>
<td>1.4</td>
</tr>
<tr>
<td>Total</td>
<td>126,608</td>
<td>100</td>
<td>2,989</td>
<td>6,992</td>
<td>5.5</td>
<td>1,613</td>
<td>1.3</td>
</tr>
</tbody>
</table>
Oregon’s COVID-19 Risk Levels

Statewide Metrics
12/27/2020 - 01/09/2021
378.9 cases per 100k residents
7.5% test positivity

COVID-19 Risk Levels
- Lower
- High
- Extreme

Hover over a county to see more information.
Hover over one of the bars below to highlight the counties in that risk level.

Oregon Counties by COVID-19 Risk Level:
- Lower: 7 counties
- High: 6 counties
- Extreme: 23 counties
Hospital COVID Census: Statewide Trends

- COVID-positive patients
- COVID-positive patients in ICU beds
- COVID-positive patients on ventilators

Filter by Patient Type:
- Positives Only

Hospitalized Patients

Date:
- 4/6
- 4/20
- 5/4
- 5/18
- 6/1
- 6/15
- 6/29
- 7/13
- 7/27
- 8/10
- 8/24
- 9/7
- 9/21
- 10/5
- 10/19
- 11/2
- 11/16
- 11/30
- 12/14
- 12/28
- 1/11
Hospital COVID Census: Statewide Trends
COVID-19 Vaccine Update
Oregon’s Vaccination Trend

Oregon’s Vaccination Trend: Doses Administered by Day

This chart shows the total number of COVID-19 vaccine doses that have been given in Oregon. *Doses administered during this time may not yet be reported.

Doses Administered
**The number of doses administered and people vaccinated may not match. Please see below for more detail.

- 129,781 Total Doses Administered
- 110,411 Series In Progress
- 9,568 Fully Vaccinated
- 119,979 Total People
The map shows the number of people vaccinated per 10,000 by county of residence. For privacy purposes, counties with the number of vaccinated people between 1 and 5 will be shown as "Suppressed."

Click on a county below to filter the data on the right. Click again to clear the filter.

### People Vaccinated

<table>
<thead>
<tr>
<th>ALL COUNTIES</th>
<th><strong>Series In Progress</strong></th>
<th><strong>Fully Vaccinated</strong></th>
<th><strong>Total People</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>110,411</td>
<td>9,568</td>
<td>119,979</td>
<td></td>
</tr>
</tbody>
</table>

### Doses Administered by Day

*Doses administered during this time may not yet be reported.*

<table>
<thead>
<tr>
<th>Date Dose Administered</th>
<th>Jan 12, 21</th>
<th>Jan 7, 21</th>
<th>Jan 2, 21</th>
<th>Dec 28, 20</th>
<th>Dec 23, 20</th>
<th>Dec 18, 20</th>
</tr>
</thead>
</table>
# Vaccinations by Demographic Group

These tables show the number of people who have received COVID-19 vaccine in Oregon by race, ethnicity, sex and age group.

## People Vaccinated by Demographic Group

<table>
<thead>
<tr>
<th>RACE†</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>American Indian / Alaska Native</td>
<td>1,929</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>6,032</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1,777</td>
<td></td>
</tr>
<tr>
<td>Native Hawaiian / Pacific Islander</td>
<td>1,003</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>84,490</td>
<td></td>
</tr>
<tr>
<td>Other Race</td>
<td>30,803</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>20,497</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ETHNICITY†</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hispanic</td>
<td>5,880</td>
<td></td>
</tr>
<tr>
<td>Not Hispanic</td>
<td>83,981</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>30,118</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AGE GROUPS</th>
<th>16 to 19</th>
<th>15,517</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 to 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 to 39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 to 49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 to 59</td>
<td></td>
<td>23,143</td>
</tr>
<tr>
<td>60 to 69</td>
<td></td>
<td>15,782</td>
</tr>
<tr>
<td>70 to 79</td>
<td></td>
<td>5,781</td>
</tr>
<tr>
<td>80+</td>
<td></td>
<td>4,652</td>
</tr>
</tbody>
</table>

## SEX

<table>
<thead>
<tr>
<th></th>
<th>Female</th>
<th>78,323</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>40,538</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>1,118</td>
</tr>
</tbody>
</table>
Total number of People Initiating Vaccination (1st Dose Received) Reported to the CDC
Looking Ahead: news this week

- Governor Brown announced that starting January 23\textsuperscript{rd}, vaccination will be expanded to include \textit{seniors 65 and older, child care providers} and \textit{early learning} and \textit{K-12 educators and staff}
- The federal government announced it will be releasing its full reserve of vaccines available to other states, rather than holding some doses in storage
  - Allocations will depend on administration level by state, no longer by population; therefore, Oregon must demonstrate utilization at the highest level
- Phase 1a vaccinations continue in the meantime, with a push to get access to those most vulnerable and disproportionately impacted from COVID-19
National Vaccination Data

Overall US COVID-19 Vaccine Distribution and Administration

- Total Doses Distributed: 29,380,125
- Total Number of People Initiating Vaccination (1st Dose Received): 10,278,462

CDC | Updated: Jan 13 2021 As of 9:00am ET

Federal Pharmacy Partnership for Long-Term Care Program (Subset of Overall Numbers)

- Doses Distributed for Use in Long-Term Care Facilities: 4,556,575
- Number of People Initiating Vaccination (1st Dose Received) in Long-Term Care Facilities: 1,084,177

CDC | Updated: Jan 13 2021 As of 9:00am ET
Challenges in Vaccine Distribution, Administration

• Distribution Challenges
  – Cold storage needs
  – Minimum dosages for shipments (975 - Pfizer, 100 Moderna)
  – Allocation challenges and unknowns
  – Inadequate federal allotments to meet the need

• Administration/throughput challenges:
  – Operational Challenges:
    • Scheduling
    • Space requirements (physical distancing)
    • Observation period post vaccination (15–30 minutes)
  – Limited outlets to give vaccine
  – Provider enrollment
  – Data lag
Vaccine Distribution To Date

• Hospitals, Tribal Health
• Local Public Health Authorities
• Emergency Medical Service and First Responders
• Urgent Care Centers
• Federal Pharmacy Partnership:
  – Part A: skilled nursing facilities
  – Part B: other long-term care facilities and other congregate care settings

• Looking ahead: larger eligible populations
Centralized, Regional Vaccine Access Points

Local Public Health Authorities

Hospital(s)/Health System(s)

Other Regional Partners
e.g., FQHCs, other

Federal Pharmacy Program

State Pharmacy Program

Must also ensure access through trusted, culturally responsive and accessible sites
Vaccine limitations

• There aren’t enough vaccines for everyone eligible
• Standard vaccination distribution process isn’t possible immediately
• For some groups the distribution has more straightforward pre-existing pathways:
  • Hospitals can vaccinate their own employees and affiliated staff
  • Federal pharmacy partnership offers pathway for skilled nursing facilities and other congregate care settings
• For other groups it’s a more complex process:
  • For example, vaccinating health care personnel who aren’t affiliated with a hospital requires Oregon’s health care system to adapt to new approaches
• As a result, we need to expand the number of administration sites and establish new collaborations to deliver new COVID-19 vaccines in new ways among all our health care partners, including those most vulnerable and disproportionately impacted from COVID-19
Work Underway

• **Part B of our federal pharmacy partnership has been activated**
  – Oregon is working with CDC and Walgreens, Consonus and CVS to activate the second phase of the federal pharmacy partnership program as soon as possible.

• **Use retail pharmacies to get more vaccines to HCW and other Phase 1A groups.**
  – Accelerate retail pharmacy involvement to make available to health care workers in Phase 1A, including mobile capability to those not included in federal pharmacy partnership.

• **Work with local partners to extend access to unaffiliated healthcare personnel such as traditional health workers and health care interpreters, as well as eligible individuals with I/DD and other disabilities**
Where can I find additional information?

• Many of your questions related to the vaccine might already be answered on our OHA COVID-19 vaccine website. We encourage you to visit this site regularly for updates.

• Clinical and operational questions regarding the COVID-19 vaccine from providers will inform our OHA COVID-19 vaccine provider page. Please visit this site regularly for updates.

• If you are a provider with COVID-19 vaccine enrollment questions, your email will be forwarded to our enrollment team. In the future you may email our provider enrollment team directly Vaccine.ProviderEnroll@dhsoha.state.or.us.

• Questions from Alert Immunization Information System users will be forwarded to the Alert IIS Helpdesk. In the future you may email our ALERT IIS Helpdesk directly alertiis@state.or.us.
Operation Warp Speed Update-12-12-21
Timeline for New Vaccines

Janssen- Non-Replicating Viral Vector Vaccine (Adenovirus 26)
• Phase 3 ENSEMBLE trial nearing completion - will likely submit for an EUA before the end of January
• Single dose (ENSEMBLE 2 Trial – ongoing is testing a 2 shot regimen)
• Normal refrigeration

AstraZeneca Non-Replicating Viral Vector Vaccine (AZD 1222)
• Likely to submit application for EUA based on data from ongoing US based phase 3 trial the 1st week of March.
• 2 dose regimen
• Normal refrigeration

Novavax: Protein Subunit with Adjuvant Vaccine (NVX-CoV2373)
• On track to complete trial and submit application for EUA late March
• 2 dose regimen (21 days apart)
• Uses nanoparticle technology with a stabilized form of the coronavirus spike protein combined with a proprietary adjuvant, Matrix M.
Coronavirus Variants and Increased Transmissibility

• 2 recent variants from the UK and South Africa show concerning increase in transmissibility. (40-70%) [https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/]
  – Tighter binding to receptor site-
• Do not appear more deadly but incr. transmission causes increased cases and ultimately increased hospitalizations and death.
• Possible effect on monoclonal antibody therapy
• mRNA vaccine creates polyclonal antibodies and still seems effective [https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1.full](https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1.full)
• Sequencing is ongoing in Oregon Oregon OHSU, UofO and OSU.
• The UK variant (B117) has been found in several states but the So. African variant has not been seen in the US yet.
B117 in the US as of 1-11-21

B.1.1.7 Lineage Cases in the United States* | Total Cases: 72

Territories: AS GU MH FM MP PW PR VI
Testing
Reminder: Point of care antigen BinaxNOW tests still available to augment testing capacity and point of care support!

- BinaxNOW point-of-care antigen COVID-19 tests require Clinical Laboratory Improvement Amendment (CLIA) certification or CLIA waiver to perform, but do not require any additional laboratory devices to process the sample. **Results can be provided to patients in as little as 15 minutes.**
- BinaxNOW antigen tests are most accurate at detecting COVID-19 in symptomatic individuals; OHA recommends they be used to test patients with symptoms consistent with COVID-19 or contacts of COVID-19 cases.
- OHA is distributing these tests at no cost to primary care and urgent care providers. If your clinic is interested in receiving an allotment of these tests from OHA, please email ORESF8.AOCTestingBranch@dhsoha.state.or.us and a member of OHA’s Testing Team will reach out to you.
- You must accept Medicare and Medicaid and have a CLIA certificate or waiver in order to be eligible to receive these tests.
Ready Schools Safe Learners Update

Updated guidance will be released on January 19, 2021
Governor Brown’s Direction:

• Stay grounded in the evidence and work together to return to in-person instruction by February 15th, especially at the elementary level.
• Partner with OHA to provide for on-site COVID-19 testing at schools.
• Health Metrics for returning to in-person instruction transition to advisory recommendations on January 1st.
• Review and possibly update the Advisory Health Metrics for returning to in-person instruction by January 19th.
• Align RSSL guidance and Oregon OSHA rules to ensure all necessary health and safety procedures and protocols are included to allow maximum access to in-person instruction.
Transition to Local Decision-Making

• At this point in Oregon’s evolution of responding to COVID-19, the assessment is that we are at a point where we can return to local decision making.

• Local schools/districts are the best judge for local capacity for meeting requirements and successfully implementing On-Site, Hybrid, and Comprehensive Distance Learning Instructional Models.

• Focus is to get the community case counts to a low enough number that the community is not regularly introducing COVID-19 into the school - which destabilizes the learning environment as contact tracing leads to quarantining.

• Local decision making better able to implement public health and safety protocols/requirements in the schools with fidelity. This includes universal use of face coverings, physical distancing, cohorting, frequent handwashing, and all of RSSL detailed guidance.
<table>
<thead>
<tr>
<th>Current Metrics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metrics &amp; Models</strong></td>
</tr>
<tr>
<td><strong>County Case Rate</strong></td>
</tr>
<tr>
<td>per 100,000 People Over 14 days</td>
</tr>
<tr>
<td><strong>County Case Count</strong></td>
</tr>
<tr>
<td>Over 14 days</td>
</tr>
<tr>
<td>Advised for small and medium counties</td>
</tr>
<tr>
<td><strong>County Test Positivity</strong></td>
</tr>
<tr>
<td>Advised for to medium and large counties</td>
</tr>
</tbody>
</table>

| Advisory Instructional Model Guidance | On-Site or Hybrid (only as needed to maintain small cohorts) instructional models. | Prioritize careful phasing in of On-Site or Hybrid for elementary schools (starting with younger students and adding additional grades over time). Middle school and high school primarily Comprehensive Distance Learning with Limited In-Person Instruction. Over time, if elementary schools demonstrate the ability to limit transmission in the school environment, transition to On-Site or Hybrid. | Consider transition to Comprehensive Distance Learning with Limited In-Person Instruction. For counties with an upward case/positivity trend entering from a lower risk category, school officials should discuss with their local public health authority (LPHA) and consider the spread of COVID-19 within schools and the local community in deciding whether to return to Comprehensive Distance Learning (CDL). Schools in counties with downward case/positivity trend should remain in CDL until they drop into the “On-Site and Distance Learning” category or lower. | Prioritize Comprehensive Distance Learning with Limited In-Person Instruction. |

**Metrics Risk Table Footnotes**

1. If statewide testing volume decreases by more than 10% in the week prior compared to the previous week due to external factors (such as due to a natural disaster or acute decrease in testing supplies), then OHA and ODE will advise temporarily suspending the use of percent positivity in local reopening considerations.

2. As a measure to monitor limited introduction or spread, local public health should look for an average outbreak size of 3 or less, excluding outbreaks with only one case, over the prior 4 weeks.

3. In considering community spread, public health should take into consideration the cases in the community, COVID-19 test availability in the community, recent percent positivity of tests, capacity in the community to respond to cases and outbreaks and the regional hospital capacity available for those with severe disease.

4. Small counties with a population of less than 15,000 are advised to meet case counts in the metrics framework and not test positivity rates.
<table>
<thead>
<tr>
<th>Metrics &amp; Models</th>
<th>On-Site</th>
<th>On-Site and Hybrid</th>
<th>Transition</th>
<th>Distance Learning</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>County Case Rate</strong>&lt;br&gt;per 100,000 People Over 14 days</td>
<td>&lt;50.0</td>
<td>50.0 to &lt;200.0</td>
<td>200.0 to ≤350.0</td>
<td>&gt;350.0</td>
</tr>
<tr>
<td><strong>County Case Count</strong>&lt;br&gt;Over 14 days (for small counties*)</td>
<td>&lt;30</td>
<td>30 to &lt;60</td>
<td>60 to ≤90</td>
<td>&gt;90</td>
</tr>
<tr>
<td><strong>County Test Positivity</strong></td>
<td>&lt;5.0%</td>
<td>5.0% to &lt;10.0%</td>
<td>≤10.0%</td>
<td>&gt;10.0%</td>
</tr>
</tbody>
</table>

**Advisory Instructional Model**
- Prioritize **On-Site** or **Hybrid** (as needed to maintain small cohorts) instructional models.
- Prioritize careful phasing in of **On-Site or Hybrid** for elementary schools (starting with younger students and adding additional grades over time).
- Middle school and high school primarily **Comprehensive Distance Learning with Limited In-Person Instruction**. Over time, if elementary schools can demonstrate the ability to limit transmission in the school environment, transition to **On-Site or Hybrid**.
- Prioritize careful phasing in of **On-Site or Hybrid** for elementary schools (starting with younger students and adding additional grades over time).
- Prioritize **Comprehensive Distance Learning with Limited In-Person Instruction**.

When trends are increasing, pause expansion of additional in-person learning and maintain access to in-person learning for those who have it. Schools are not required to reduce in-person learning or revert to Comprehensive Distance Learning based on metrics if the school can demonstrate the ability to limit transmission in the school environment.
Rapid COVID-19 testing in schools:

• OHA and ODE recognize in-person instruction is critical to child development and should be prioritized over other social goods.
• In order to mitigate the risk of school reopening, OHA will offer rapid COVID-19 testing resources directly to schools (BinaxNOW test kits)
• Testing delays have been shown to increase household transmission of COVID-19:
  – Preprint publication (Paul et al, 2020) showed 3-fold increased risk of HH transmission associated with a testing delay of 5 days vs. 0
• Rapid testing on campus gives students and staff immediate and equitable access.

Recommendation:
• Test all students and staff who develop symptoms promptly
• Test all students and staff exposed to a case within their cohort(s)
COVID-19 Literature Updates
MMWR article on COVID and kids

- Just under 900 kids, wide age range
- Case-control study using data from a testing center in Mississippi
- Compared various exposures reported by parents or guardians of children and adolescents aged <18 years pos PCR test (case-patients) with exposures reported among those who received negative test results (controls)
- Results suggest that **schools where not where kids get COVID** (14 days prior to test, in-person school vs not)
- Face mask use in schools was reported: consistent face mask use reported associated with neg tests (aOR 0.4, CI 0.2-0.8)
- Close contacts with confirmed COVID, attending gatherings/social functions, activities with other children, and visitors in the home were the main associations with positive test results, all statistically significant

*What it means to us: like with much of the literature being published lately (US and international), if people adhere to safety precautions, suggests that in-person school is fairly safe*

https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm?s_cid=mm6950e3_w
Other references re schools and COVID

- [https://pediatrics.aappublications.org/content/early/2021/01/06/peds.2020-048090](https://pediatrics.aappublications.org/content/early/2021/01/06/peds.2020-048090)
- [https://pediatrics.aappublications.org/content/pediatrics/early/2021/01/06/peds.2020-048090.full.pdf](https://pediatrics.aappublications.org/content/pediatrics/early/2021/01/06/peds.2020-048090.full.pdf)
- [https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm?s_cid=mm6950e3_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm?s_cid=mm6950e3_w)
Opioid Overdoses Deaths During COVID

- CDC, December 17, 2020
  - 81,230 drug overdose deaths occurred in the United States in the 12 months ending May 2020
    - Highest 1 year total ever
    - Largest increase documented from March 2020 to May 2020, a time when widespread mitigation measures were implemented.
  - Main driver of increased overdose deaths appears to be fentanyl
  - Overdose deaths involving cocaine also increased by 26.5 percent
    - Concern for illicit mixing with heroin or fentanyl
  - Overdose deaths involving psychostimulants, such as methamphetamine, increased by 34.8 percent
Opioid Overdoses Deaths During COVID

- CDC recommending the following actions as appropriate based on local needs and characteristics:
  - Expand distribution and use of naloxone and overdose prevention education.
  - Expand awareness about and access to and availability of treatment for substance use disorders.
  - Intervene early with individuals at highest risk for overdose.
  - Improve detection of overdose outbreaks to facilitate more effective response
Opioid Overdoses Deaths During COVID

• CDC recommending the following actions as appropriate based on local needs and characteristics:
  – Expand distribution and use of naloxone and overdose prevention education.
  – Expand awareness about and access to and availability of treatment for substance use disorders.
  – Intervene early with individuals at highest risk for overdose.
  – Improve detection of overdose outbreaks to facilitate more effective response
Non Fatal Overdoses During COVID

- Ochalek et al, JAMA September 18, 2020
  - Virginia Commonwealth University ER visit data
  - The total number of nonfatal opioid overdose visits increased from 102 between March and June 2019 to 227 between March and June 2020
  - Similar rates of Naloxone prescriptions in both time periods
  - Limitations: single center study
  - This study highlights the need for emergency clinicians, communities, and healthcare systems to aggressively promote harm-reduction strategies and help appropriate patients begin treatment with medication for OUD
Upcoming Health Care Provider Sessions on COVID-19

2nd Thursdays: OHA COVID-19 Information Session for HCPs*
1st and 3rd Thursdays: Project Echo COVID-19 Response for Clinicians Part II^

*Oregon Health Authority COVID-19 Information Sessions for Oregon Health Care Providers
  – Session information, slides and recordings at: www.healthoregon.org/coronavirushcp

^OHSU’s COVID-19 Response ECHO for Oregon Clinicians Part 2
  – https://connect.oregonechonetwork.org/Series/Registration/278
Thank you